Genetron Health
Specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment.
Market cap
$127m
Enterprise value
$103m
Share price
$4.03 GTH
Recent deals
loading funding rounds…
Alexandria Venture Investments(exited)
Highlight Capital(exited)
Vivo Capital(exited)
Share Capital(exited)
New Horizon Capital(exited)
Zhongyuan Union Cell & Gene Eng(exited)
Origene Technologies(exited)
| CNY | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 127 % | 31 % | 31 % | 25 % | 22 % | 18 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (395 %) | (94 %) | (193 %) | (718 %) | (87 %) | (84 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (416 %) | (207 %) | (209 %) | (723 %) | (93 %) | (124 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 45 % | 32 % | 28 % | 35 % | 48 % | 45 % | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Genetron Health
Edit
ACQUISITION by Genetron Health Oct 2023